- Strong match: 3 shared modalities
- Strong match: 3 shared learner audiences
- Also shares: professional level
- Also shares: hybrid delivery
Back to StakeholdersDrug Science Experiential Training Institute MIND Foundation OPEN Foundation
Categories
2 domains / 4 areas / 2 specializations
COMPASS Pathways
Data updated
United Kingdom
15 Trials2 Papers
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
ProfessionalHybridPremiumPsychedelic-assisted therapy trainingContinuing educationAcademic programmeLicensed cliniciansResearchersOther
Blossom’s read
COMPASS Pathways is best understood as a serious clinical-development company rather than a broad public training school. Its therapist programme appears to have been built for regulated trial delivery and commercial readiness, with a notable evidence-based lineage and input from established academics and clinicians in psychology, psychiatry and psychedelic research. In the field, that gives it credibility and structure, but also means it is most relevant to professionals operating in formal healthcare or research settings rather than to general interest learners.
Who COMPASS Pathways is for
Best suited to licensed clinicians and clinical-research staff who are involved, or expect to be involved, in psilocybin-assisted therapy delivery within regulated settings. It is less obviously aimed at the curious public or at standalone facilitators outside medical systems.
Prerequisites
The materials support that therapists are employed by clinical trial sites and that the programme is for healthcare professionals working in psilocybin therapy. Specific licensure or entry requirements are not clearly stated in the sources reviewed.
Accreditation & recognition
Compass says the therapist training programme was published in a peer-reviewed paper in Frontiers in Psychiatry, and its materials describe it as designed by experts and approved by the FDA for research purposes. I did not find clear evidence of formal third-party accreditation, CME, or CE credit for the programme in the sources reviewed.
Cost
No public tuition pricing was found. For the research context, Compass states it provides cGMP COMP360 psilocybin to researchers free of charge, while researchers cover packaging and shipping. That appears separate from any therapist training cost, which was not disclosed.
What you walk away with
Learners appear to gain a structured competency framework for supporting preparation, dosing and integration sessions in COMPASS-sponsored psilocybin research, with mentoring and professional development. The practical outcome is readiness to work on clinical trials or, more broadly, within Compass-aligned psilocybin care pathways.
Similar course providers
Reference points selected from shared training modalities, learner audience, level, delivery format, pricing, and location.
- Strong match: 2 shared modalities
- Strong match: 2 shared learner audiences
- Also shares: professional level
- Also shares: hybrid delivery
- Strong match: 3 shared modalities
- Strong match: 3 shared learner audiences
- Also shares: professional level
- Also shares: hybrid delivery
- Strong match: 3 shared modalities
- Strong match: 3 shared learner audiences
- Also shares: professional level
- Also shares: hybrid delivery
Quick Facts
- Type
- Public Biotech
- HQ
- United Kingdom
- Website
- Visit